ECB Eyes Rate Hike Amid Iran Conflict-Driven Energy Price Surge 
OpenAI Pulls the Plug on Sora, Ending $1 Billion Disney Partnership 
FDA Warns Novo Nordisk Over Misleading Ozempic Ad Claims 
U.S. Stock Futures Steady as Iran Reviews U.S. Ceasefire Proposal 
Trump Tariffs Show Minimal Economic Impact but Boost Federal Revenue, Study Finds 
Asian Currencies Stay Muted as Dollar Holds Firm Amid Iran Uncertainty 
Federal Reserve Balance Sheet Reduction: Brookings Research Outlines Possible Path Forward 
Australia's Inflation Eases in February but Core Pressures Persist 
UK Consumer Confidence Weakens Amid Middle East Conflict and Rising Living Costs 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
WTO Reform Talks Begin in Cameroon Amid Global Trade Tensions 
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Sonova Shares Slip as Hearing Aid Giant Lowers Growth Outlook and Plans Sennheiser Exit 
Berkshire Hathaway and Tokio Marine Form Major Strategic Insurance Partnership 
SK Biopharmaceuticals, the South Korean pharmaceutical giant, projects $1 billion in U.S. sales by 2029 for its flagship anti-epilepsy treatment, Xcopri. The firm, combating a sales decline in 2020, hopes this drug will bolster its financial turnaround, positioning it as a global biotech leader.
Xcopri, or cenobamate, is a medication developed by SK Biopharmaceuticals and its U.S. subsidiary SK Life Science for treating partial-onset seizures in adults. It was approved for medical use in the U.S. at the end of 2019 and in Europe in 2021. In Europe, it is marketed under the brand name Ontozry.
The total prescriptions (TRx) for Xcopri, a key metric used in the pharmaceutical industry to measure a medicine's launch performance, have reached 22,000 monthly in the U.S. market this year. This number is projected to grow to 30,000 per month next year, establishing Xcopri as a leading anti-epilepsy treatment in the U.S. Lee Dong-hoon, CEO of SK Biopharmaceuticals, said they anticipate U.S. sales for Xcopri to break even by the end of this year and to reach $1 billion by 2029 and skyrocket to $3.5 billion by 2032.
In 2020, SK Biopharmaceuticals reported a significant decline of 50.8% in sales, amounting to 456.7 billion won ($362 million). However, Xcopri, with a gross profit margin of 90%, is expected to contribute to the company's financial growth.
The CEO emphasized the valuable stability that Xcopri will bring to the company's future revenue streams, allowing for an expansion of SK Biopharmaceuticals' business portfolio to become a global biotech platform company.
Lee stated that the company would enhance its therapeutic modalities, focusing on radiopharmaceutical therapy (RPT), a groundbreaking approach that delivers radiation therapy directly to cancer cells. SK Biopharmaceuticals aims to secure rights for radioisotope supply, which is crucial for RPT medications, through collaboration with TerraPower, a U.S. venture founded by Bill Gates that specializes in small-sized nuclear power reactors. Lee highlighted the significance of the cell and gene therapy sector as another key area of focus for SK Biopharmaceuticals moving forward.
In addition, SK Biopharmaceuticals will strengthen its targeted protein degradation (TPD) platform. This effort follows the recent acquisition of Proteovant Therapeutics, a U.S. biotech company with advanced TPD technology that can effectively target disease-causing proteins.
As the company expands its capabilities and ventures into new territories, it aims to position itself as a global biotech leader with a unique business model, transitioning from a single asset-based company to a comprehensive powerhouse.
Photo: Hal Gatewood/Unsplash
